BACKGROUND. @entity14 ( @entity14 ) can be prevented. Colonoscopy is the first-line procedure for screening in average risk population. In 2002, Imperiale evaluated @entity1 between 40 to 49 years and reported that @entity652 and advanced @entity652 presented in 8.5% and 3.5% of cases, respectively. Currently, no recommendations for @entity14 screening in this population have been made. OBJECTIVE: To estimate the prevalence ofpolyps, @entity652 , @entity1442 and @entity420 in the 45- to 49-year-old population. METHODS: We included consecutive adults between 45 and 49 years old who performed colonoscopy because of gastrointestinal signs or symptoms. Exclusion criteria were high risk for @entity14 , incomplete VCC and/or previous evidence of @entity1049 . The study was conducted in a gastroenterology center from Buenos Aires, between September 2010 and October 2011. The design was prospective and cross-sectional. @entity968 ( @entity970 ) lavage solution or @entity6546 were usedfor cleansing. Colonoscopies were performed under sedation with Olympus equipment. The protocol was approved by the local IRB. 95% confidence intervals (95% CI) were estimated. RESULTS: 814 @entity1 were evaluated and 764 were included, 440 (57%) were @entity1 and the average age was 47 years. The global prevalence of @entity1127 was 20% (160 cases, 95% CI 18%-24%). The global prevalence of @entity652 was 14% (107 cases, 95% CI 11%-16%). The prevalence of advanced @entity652 was 5% (39 cases, 95% CI 4%-7%) and the prevalence of @entity420 was 0.1% (1 case, 95% CI 0%-0.7%). CONCLUSIONS: The prevalence of lesions in this population is lower than that in the average risk population. At the moment we do understand that there is no evidence to recommend @entity14 screening in 45- to 49-year-old individuals.

[Detection of @entity1127 , @entity652 , advanced @entity652 and XXXX in @entity1 between 45 and 49 years].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'people'] @entity1127 :: ('MESH:D011127', 'Disease') :: ['polyps'] @entity6546 :: ('MESH:D010710', 'Chemical') :: ['phosphates'] @entity968 :: ('MESH:D011092', 'Chemical') :: ['Polyethylene glycol'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced lesions'] @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'CRC'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma'] @entity970 :: ('CHEBI:46793', 'Chemical') :: ['PEG'] @entity1049 :: ('MESH:D003108', 'Disease') :: ['colonic lesions']
@entity420 :: (MESH:D000230,Disease) :: ['adenocarcinomas']
